MARVIN MOSER, M.D.
This content is PDF only. Please click on the PDF icon to access.
The Direct Cost involved in the treatment of hypertension in the United States has been estimated at approximately $8 billion a year, with more than $1.5 billion being spent on antihypertensive drugs (1). Recent surveys have reported that a significant number of patients with hypertension (20% to 35%) find the cost of drugs to be an obstacle to treatment (2-4). This number has increased during the past 3 to 4 years because newer, more expensive, and heavily promoted drugs have become available. The cost may also have increased further as pressure mounted to use newer forms of technology in the
MOSER M. "Cost Containment" in the Management of Hypertension. Ann Intern Med. 1987;107:107–109. doi: 10.7326/0003-4819-107-1-107
Download citation file:
Published: Ann Intern Med. 1987;107(1):107-109.
Cardiology, Coronary Risk Factors, Healthcare Delivery and Policy, HIV, Hypertension.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use